2025 年 09 月 02 日 机构关注度环比回升：机械、医药、汽车 策略研究团队 ——机构调研周跟踪 韦冀星（分析师） 简宇涵（分析师） weijixing@kysec.cn jianyuhan@kysec.cn 证书编号：S0790525050005 "机构调研信息"是投资者决策过程当中，重要的信息补充 机构调研信息是对基本面信息的重要补充，但信息量大且杂乱。为了清晰梳理 出调研中有效、增量信息，我们推出机构调研周跟踪系列，汇总最近一周、一 个月公开的机构调研信息，涵盖行业、个股两维度，包含调研热度（环比、同 比数据）、调研获得的行业及个股信息增量。 机构调研是资本市场信息传递和价值挖掘的重要环节。对于专业机构而言，是深 度研究、投资决策的关键步骤。相较财务信息，机构调研具备披露及时、信息多 维且深入等优势。往往在调研结束后 1-2 天内，公司以公告方式对外披露，主要 内容包含参会人员信息、会议问答等，投资者与公司管理层之间的问答往往涉及 行业最新动态及公司运营细节。 行业视角看机构调研情况: 机械设备、医药生物、汽车等关注度环比增加 周度：上周，全 A 的被调研总次数持续回升，但仍低于 2024 年同 ...

2025年以来，康泰医学（300869）(300869.SZ)加快新技术、新产品的开发应用和市场转化，积极调整 市场营销策略，稳步推进全球化布局，推动精益生产降本增效，提升经营管理质量和效益，国内外业务 实现稳步发展。 财报显示，2025年1-6月，康泰医学实现营业收入21,754.95万元，同比增长2.72%；归属于上市公司股东 的净利润达到1693.76万元，较上年同期增长107.39%；扣非归母净利润为1245.35万元，同比大幅增长 423.17%。 研发投入上，研发创新是康泰医学保持竞争力的关键。今年上半年，公司投入研发费用4648.11万元， 以高水平的研发投入带动技术创新和产品集成创新，并通过提高工艺设计能力、完善管理流程、降低材 料成本、研发团队培训等方式提升了整体研发效能。 报告期内，公司新增国内专利61项，其中发明专利3项，实用新型专利22项，外观设计专利36项，软件 著作权117项，截至报告期末，公司及子公司共获得国内外有效专利484项，计算机软件著作权369项以 及大量的技术储备。研发创新能力已经成为公司的核心竞争力之一。 业绩稳步增长，康泰医学表示主要有以下三方面原因：人口老龄化进程 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a steady performance in Q2 2025, with revenue growth driven by the electronic materials and new energy sectors, alongside stable growth in the catalytic materials segment [5][6] - In the first half of 2025, the company achieved revenue of 2.154 billion yuan, a year-on-year increase of 10.29%, and a net profit attributable to shareholders of 332 million yuan, a year-on-year increase of 0.38% [4][5] - The company is expanding its product offerings across multiple sectors, including automotive electronics, AI computing servers, and solid-state battery materials, which are expected to contribute to future growth [6][7] Financial Performance Summary - For Q2 2025, the company reported revenue of 1.179 billion yuan, a year-on-year increase of 4.67% and a quarter-on-quarter increase of 20.97% [4] - The net profit for Q2 2025 was 196 million yuan, a year-on-year decrease of 0.57% but a quarter-on-quarter increase of 44.33% [4] - The company expects net profits for 2025-2027 to be 798 million, 913 million, and 1.16 billion yuan respectively, with year-on-year growth rates of 32.0%, 14.5%, and 26.9% [8] Business Segment Insights - The electronic materials segment is experiencing high growth due to increasing demand for automotive electronics and AI applications, with successful product validation from key clients [5] - The catalytic materials segment has gained traction by supplying ceramic substrates and other products to major international automotive manufacturers [5] - The biomedical materials segment is advancing with the development of dental restoration products, which have begun to see market acceptance [5] - The new energy materials segment is focusing on ultra-thin coatings and has developed various new product models in response to customer needs [5][6]

Investment Rating - The report maintains an "Accumulate" rating for the company [1] Core Views - The company has shown steady performance with a diversified layout contributing to growth in 2024 and Q1 2025, driven by recovery in consumer electronics, automotive, and dental medical sectors [5][6] - The company achieved a revenue of 4 billion CNY in 2024, a year-on-year increase of 5%, and a net profit of 600 million CNY, up 6% year-on-year [5] - In Q1 2025, the company reported a revenue of 975 million CNY, an 18% increase year-on-year, and a net profit of 136 million CNY, a 2% increase year-on-year [5] Summary by Sections Financial Performance - In 2024, the company’s revenue was 40 billion CNY, with a net profit of 6 billion CNY, while Q4 alone contributed 10.8 billion CNY in revenue [5] - The Q1 2025 results showed a revenue of 9.75 billion CNY and a net profit of 1.36 billion CNY [5] Business Segments - The electronic materials segment benefited from recovering downstream demand, with MLCC medium powder sales gradually increasing [6] - The catalytic materials segment successfully overcame technical barriers, meeting stringent vehicle emission standards, and saw rapid growth in sales due to increased demand from overseas clients [6] - The biomedical segment received EU medical device compliance certification for several products, enhancing market recognition and paving the way for accelerated promotion in Europe [6] Growth Opportunities - The company is strategically positioned in the new energy sector, launching several lithium battery additives and becoming a major supplier in the industry [7] - The LED substrate segment has strengthened its competitive edge through technological synergies, while the communication RF micro-system chip packaging business is expected to become a significant growth point [7] - The subsidiary has made strides in digital printing materials, aiming to become a leader in the Chinese market [7] Profitability and Valuation - The report adjusts the profit forecasts for 2025-2026 downwards by 20%, with expected net profits of 754 million CNY and 914 million CNY respectively, while introducing a forecast for 2027 at 1.13 billion CNY [8][9] - The company’s EPS is projected to be 0.76 CNY for 2025, 0.92 CNY for 2026, and 1.13 CNY for 2027 [8][9]

Investment Rating - The report maintains an "Accumulate" rating for the company [1] Core Views - The company has shown steady performance with a diversified layout contributing to growth in 2024 and Q1 2025, driven by recovery in sectors such as consumer electronics, automotive, and dental healthcare [5][6] - The company achieved a revenue of 4 billion CNY in 2024, a year-on-year increase of 5%, and a net profit of 600 million CNY, up 6% year-on-year [5] - In Q1 2025, the company reported a revenue of 975 million CNY, an 18% increase year-on-year, and a net profit of 136 million CNY, a 2% increase year-on-year [5] Summary by Sections Performance Overview - In Q4 2024, the company recorded a revenue of 1.08 billion CNY, a 1% increase year-on-year and a 7% increase quarter-on-quarter, with a net profit of 123 million CNY, down 4% year-on-year and 19% quarter-on-quarter [5] - The electronic materials segment benefited from recovering downstream demand, particularly in automotive electronics and AI servers, leading to a gradual increase in MLCC dielectric powder sales [6] Strategic Developments - The company has made significant advancements in catalyst materials, successfully overcoming technical barriers to meet stringent vehicle emission standards, which has led to increased demand from overseas clients [6] - In the biomedical sector, the company’s zirconia ceramic blocks and glass ceramic blocks have received compliance certification under EU medical device regulations, enhancing market recognition and paving the way for accelerated promotion in Europe [6] Financial Projections - The report adjusts the profit forecasts for 2025-2026, projecting net profits of 754 million CNY and 914 million CNY respectively, with an estimated EPS of 0.76 CNY and 0.92 CNY [8][9] - The company’s revenue is expected to grow to 4.77 billion CNY in 2025, reflecting an 18% growth rate, with a net profit growth rate of 24.72% [9][10] Valuation Metrics - The report provides a valuation with a P/E ratio of 22 for 2025, decreasing to 15 by 2027, indicating a favorable long-term outlook [12][13] - The company’s gross margin is projected to stabilize around 40% in the coming years, despite slight declines in specific segments [12]